A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Clinical trial NCT06680258 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06680258
- Sponsor
- Tempest Therapeutics
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-01
- Primary completion
- 2028-12-01
- Enrollment
- 740
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.